PharmEasy Unlisted Share Price
As of , the indicative unlisted share price of PharmEasy is ₹5.60 per share. This is an over-the-counter reference price, not a stock-exchange quote.
As of , PharmEasy is not listed on any Indian stock exchange (NSE or BSE) — its shares trade in the unlisted, over-the-counter (pre-IPO) market.
| Price / unit | ₹5.60 |
|---|---|
| Market cap | ₹9,538 Cr |
| Min. investment | ₹10,024 |
| Lot size | 1,790 |
| P/B ratio | 2.77 |
| Book value | ₹1.75 |
What is PharmEasy?
PharmEasy is an unlisted Healthcare company whose shares trade in India's over-the-counter (pre-IPO) market and settle in demat form (NSDL/CDSL).
PharmEasy is the consumer-facing brand operated under API Holdings Limited, one of India's largest digital healthcare and e-pharmacy platforms. The business connects patients, pharmacies, diagnostic labs, and hospitals through a single technology layer, allowing users to order prescription and over-the-counter medicines, book diagnostic tests, schedule teleconsultations, and access health products for home delivery. Over time the group expanded from a pure online pharmacy into a broader healthcare ecosystem spanning retail distribution, business-to-business pharmaceutical supply, diagnostics, and software tools for clinics and pharmacies. The company scaled rapidly through both organic growth and acquisitions, most notably the buyout of the diagnostics chain Thyrocare, which added a large pathology and laboratory network to the platform. Its operations cover thousands of pin codes across India, supported by a network of fulfilment centres, partner pharmacies, and logistics infrastructure. This multi-segment model positions API Holdings as a vertically integrated player addressing several parts of the healthcare value chain rather than a single product line. API Holdings has been backed by a roster of prominent venture capital and private equity investors and was, at its peak, valued among India's most highly funded healthcare startups. The company filed draft IPO papers with the market regulator but subsequently withdrew them, choosing instead to strengthen its balance sheet through rights issues aimed at reducing debt and funding continued operations. As a result, its equity shares remain unlisted and are quoted on private secondary markets at an indicative level. PharmEasy draws interest in the unlisted segment because of its brand recognition, its scale across pharmacy and diagnostics, and its status as a closely watched company whose eventual listing intentions remain a subject of market attention. The indicative price reflects negotiated transactions between buyers and sellers in the unlisted space and can move with funding rounds, financial disclosures, and broader sentiment toward digital healthcare. The figures shown here are indicative market data points for information only and do not constitute any form of advice.
Key events & news
Explore more unlisted shares
Other companies in our curated selection.
Frequently asked questions
No. As of 16 July 2026, PharmEasy is an unlisted company whose shares trade over-the-counter; it would list only if and when it completes an IPO.
The minimum lot is 1,790 share(s); at the indicative price of about ₹5.60, that is approximately ₹10,024. Indicative reference, not a quote.
As of 16 July 2026, the indicative unlisted share price of PharmEasy is ₹5.60 per share. This is an over-the-counter reference price, not a stock-exchange quote.
PharmEasy is the consumer brand of API Holdings Limited, a digital healthcare and e-pharmacy platform. It lets users order prescription and over-the-counter medicines, book diagnostic and lab tests, access teleconsultations, and buy health products online, and it also operates in pharmaceutical distribution and diagnostics, including the Thyrocare lab network.
No. PharmEasy's parent, API Holdings Limited, is not listed on the NSE or BSE. It filed draft IPO papers and later withdrew them, so its shares remain unlisted. Unlisted shares are bought and sold privately through SEBI-registered intermediaries and unlisted-share platforms, with shares transferred into the buyer's demat account against the negotiated price.
The indicative price reflects negotiated transactions between buyers and sellers in the private secondary market rather than an exchange quote. It can be influenced by the company's financial performance, fundraising rounds such as rights issues, debt levels, demand and supply among unlisted investors, and overall sentiment toward digital healthcare. The figure is indicative only and may differ from one platform to another.
PharmEasy's shares are issued under API Holdings Limited, with ISIN INE0DJ201029, CIN U60100MH2019PLC323444, and a face value of ₹1 per share. The company was incorporated in 2019 and is registered in Mumbai, Maharashtra. These are factual reference details and not a recommendation to transact.
They can. If the company declares a dividend, unlisted shareholders are eligible like any other shareholder. Many unlisted firms reinvest profits, so dividends are not guaranteed.
After listing, unlisted shares convert into regular listed shares in your demat account and can be traded on the exchange, usually once any applicable SEBI lock-in period ends.
Unlisted shares are less liquid than listed shares. You can sell when a buyer is available through an off-market transfer; there is no continuous exchange market, so exits can take longer.
Unlisted shares carry higher risk and lower liquidity than listed shares, with fewer disclosures and no live market price. This is general information, not investment advice — assess suitability before investing.
An unlisted share price is an indicative, over-the-counter reference set by demand and supply in private deals between buyers and sellers. There is no live exchange quote, so prices can vary across dealers and over time.
Yes. Unlisted shares are delivered in dematerialised form, so you need an active demat account (NSDL or CDSL). No special account type is required — a regular demat account works.
Unlisted shares are sold through an off-market transfer to a buyer via a registered intermediary, settling from your demat account with a contract note. Liquidity depends on buyer availability, so exits can take longer than listed shares.
PharmEasy vs similar unlisted Healthcare shares
Indicative over-the-counter prices, as of 16 July 2026. Information only — not a recommendation or ranking.